Related Experiment Video

Updated: May 29, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

Christopher Lieu1, John Heymach, Michael Overman

  • 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 29, 2011
PubMed

Insights

Fibroblast growth factor (FGF) signaling is implicated in cancer growth and resistance to anti-VEGF therapies. Targeting both VEGF and FGF pathways may improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Fibroblast growth factor (FGF) signaling is crucial for normal cellular functions including proliferation, differentiation, survival, and angiogenesis.
  • Aberrant FGF signaling is increasingly recognized as a driver in tumorigenesis.
  • Emerging evidence suggests FGF signaling contributes to resistance against anti-VEGF therapies in cancer.

Purpose of the Study:

  • To review the role of FGF signaling in cancer development.
  • To explore the involvement of FGF signaling in anti-VEGF therapy resistance.
  • To discuss the therapeutic potential of targeting FGF pathways in oncology.

Main Methods:

  • Literature review of studies on FGF signaling in cancer.
  • Analysis of research on the interplay between VEGF and FGF pathways.
  • Evaluation of early-stage therapeutic agents targeting FGF signaling.

Main Results:

  • Deregulated FGF signaling is a significant factor in tumorigenesis.
  • FGF signaling pathways appear to mediate resistance to anti-VEGF treatments.
  • Agents targeting FGF signaling are under development.

Conclusions:

  • FGF signaling plays a multifaceted role in cancer, influencing growth and treatment response.
  • Combined targeting of VEGF and FGF pathways holds promise for enhancing cancer therapy.
  • Further development of FGF-targeted agents is warranted for clinical application.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

In Vitro Model of Coronary Angiogenesis08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...